Determining the optimal dose and schedule of sunitinib

Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptors. In this issue, Barrios et al present a study in which 120 treatment‐naive patients with metastatic RCC were enrolled in a single‐arm, open‐label, phase 2 trial of continuous once‐daily sunitinib. This study and other data provide insight into optimal dosing of sunitinib in metastatic RCC.